The history of dopamine and levodopa in the treatment of Parkinson's disease

@article{Fahn2008TheHO,
  title={The history of dopamine and levodopa in the treatment of Parkinson's disease},
  author={Stanley Fahn},
  journal={Movement Disorders},
  year={2008},
  volume={23}
}
  • S. Fahn
  • Published 2008
  • Psychology, Medicine
  • Movement Disorders
The discoveries of dopamine as a neurotransmitter in the brain, its depletion in patients with Parkinson disease, and its replacement with levodopa therapy were major revolutionary events in the rise to effective therapy for patients with this disorder. This review describes these events and the persons who carried out these accomplishments. Their impact went beyond a single clinical entity of parkinsonism, for it opened up the beginning of a much better understanding of the role of dopamine in… 
Nondopaminergic treatments for Parkinson’s disease
TLDR
Current and experimental nondopaminergic pharmacological approaches to treatments for Parkinson’s disease with a focus on motor symptoms, treatments of L-dopa-induced motor complications and treatments of nonmotor symptoms including mood disorders, cognition, psychosis and autonomic problems are reviewed.
Levodopa therapy for Parkinson disease
TLDR
Highlights in the early development of levodopa therapy are reviewed and an overview of emerging drug delivery strategies that show promise for improvinglevodopa's pharmacologic limitations are provided.
The serotonergic system in Parkinson's disease
Recent advances in dopaminergic strategies for the treatment of Parkinson’s disease
TLDR
An overview of the current pharmacotherapies for Parkinson’s disease, the clinical development status of novel dopaminergic agents, and the challenge and opportunity of emerging preclinical dopamine approaches aimed at managing the features and progression of PD are provided.
Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson’s disease
TLDR
CLE has a good efficacy, safety and tolerability profile, similar to that of entacapone taken separately with carbidopa/levodopa (CL), and compared to CL alone, it prolongs levodopa’s benefit, and improves the quality of life but not the motor performance in PD patients with nondebilitating "wearing-off” or dyskinesia.
Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies.
Pharmacotherapies for Parkinson’s disease symptoms related to cholinergic degeneration
TLDR
The idea that enhancing cholinergic tone by pharmacological or neurosurgical procedures could be a first-line therapeutic strategy for the treatment of symptoms derived from cholinerential degeneration in Parkinson’s Disease is explored.
Dopamine Reuptake Inhibitors in Parkinson’s Disease: A Review of Nonhuman Primate Studies and Clinical Trials
TLDR
Alternative approaches to dopamine replacement in parkinsonism generally and to wearing-off and dyskinesia are urgently needed, and a hypothesis as to how tailoring the selectivity of DAT inhibitors might maximize the benefits of Dat inhibition in PD is proposed.
From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease.
  • P. Jenner
  • Psychology, Biology
    Parkinsonism & related disorders
  • 2009
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 142 REFERENCES
Treatment of parkinsonism with levodopa.
TLDR
Under the most optimal circumstances, the best that can be expected from their judicious administration is a 20% reduction in the severity of symptoms with a modest improvement of functional capacity.
Levodopa and the progression of Parkinson's disease.
TLDR
The clinical data suggest that levodopa either slows the progression of Parkinson's disease or has a prolonged effect on the symptoms of the disease, and the neuroimaging data suggest either thatlevodopa accelerates the loss of nigrostriatal dopamine nerve terminals or that its pharmacologic effects modify the dopamine transporter.
Dopamine metabolism in Parkinson's disease
TLDR
The urinary excretion of HVA was measured in patients with Parkinson's disease and to observe the clinical and biochemical effects of drug administration in these patients to measure the pathways of dopamine metabolism.
"ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPY
Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor.
TLDR
In 26 adults with Parkinsonism less levodopa was needed for symptomatic control when levodOPA was given with inhibitor than when used alone, and the amount of inhibitor that had to be added to similar doses of levodopoline was less in patients who had received levod opium chronically.
Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.
A controlled release preparation of levodopa-carbidopa, CR III, given every 4 hours to 17 Parkinsonian patients for up to 10 months reduced plasma drug variations and improved motor response
Dihydroxyphenylalanine in extrapyramidal disease.
TLDR
Findings suggest the possibility that a disturbance in the synthesis or degradation of dopamine might be involved in the etiology of extrapyramidal disturbances.
Evidence to support early levodopa therapy in Parkinson disease
TLDR
In sum, delaying therapy fails to improve disability in the early years of disease and does not confer any benefit in later years.
...
1
2
3
4
5
...